Blog

The human brain is probably the most complex structure in the universe. It is therefore not surprising that clinical trials for CNS diseases pose various challenges.

The COVID-19 pandemic is of particular concern for cardiovascular and metabolic trials because the subjects recruited are typically older with underlying cardiovascular disease and/or diabetes.

Rapid progress in connectivity and technology is inspiring innovative clinical trial design.

Increasing evidence supports that influenza infections can be a trigger for acute myocardial infarction (AMI) and stroke.

The international response to Coronavirus is focused on a number of key steps; containing the disease, saving the lives of those infected and developing vaccines.

Immunotherapy has been the focus of medical research for many years, and scientists continue to experiment with and learn about the form of therapy in cancer treatment.

FDA has upgrade the Investigational New Drug (IND) safety reporting from paper eCTD format to E2B format, improving potential safety signals in clinical studies.

The objective of this study was to estimate the cost of treatment-resource use and costs associated with sick leave (SL) and early retirement (ER) in patients below the age of 60 years with AML.

Significant progress has been made in our understanding of the molecular lesions responsible for tumor cells to exhibit uncontrolled growth.

The current wave of emerging digital technologies offers an opportunity to significantly disrupt pharma business operating models in a variety of ways.

The use of digital technology in clinical trials is creating more convenient, engaging and innovative treatments for patients.

According to a survey conducted by ICON in July 2019, prescription drug cost effectiveness analyses by the Institute for Clinical and Economic Review (ICER) are playing an increasingly important role in price negotiations.

Overcoming these challenges can greatly improve chances for a successful rare or orphan drug trial.

The integration and mastery of digital technologies is becoming essential to improve the efficiency of clinical trial operations.

NASH is massively under-diagnosed, partly because it is a silent disease and partly because definitive diagnosis is by histopathology of a liver biopsy with associated risks.

Less than one year remains before the European Union’s new Medical Device Regulation (MDR) goes into effect on May 26, 2020, and only about a fourth of medical device companies plan to be fully complaint,

The key to success in the medical device market is to ensure that value benefits align across stakeholders, especially with the payers.

Hybrid CSS-MCR studies can be advantageous in generating real world evidence to answer epidemiology questions efficiently and effectively.

A new era is emerging in which clinical practice and clinical research inform one another through RWE.

Using Big Data and AI to return pharma productivity to sustainable levels.